Fluorouracil Accord 50 mg/ml

DRUG6 trials

Sponsors

Amsterdam UMC, Catharina Ziekenhuis Stichting, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Conditions

Borderline resectable pancreatic cancer (BRPC)Non-metastatic resectable pancreatic cancerPancreatic cancerPatients with colorectal peritoneal metastases with a PCI-score of 1-20Resectable pancreatic cancer (RPC)non-metastatic (borderline) resectable pancreatic canceroesophageal canceroesophagogastric junction cancer

Phase 1

Neoadjuvant Triple Treatment with mFOLFIRINOX, pembrolizumab and SABR in patients with (borderline) resectable pancreatic cancer (PREOPANC-5): a multicenter single arm phase Ib/II trial of the Dutch Pancreatic Cancer Group

RecruitingCTIS2023-508707-20-00

Amsterdam UMCBorderline resectable pancreatic cancer (BRPC), Pancreatic cancer, Resectable pancreatic cancer (RPC)

Start: 2024-09-19Target: 66Updated: 2025-12-15

Phase 2

Personalized dosing of FOLFIRINOX in pancreatic cancer patients: a phase-2 pharmacokinetic, safety and feasibility trial

RecruitingCTIS2024-510576-21-00

Catharina Ziekenhuis StichtingPancreatic cancer

Start: 2024-09-18Target: 100Updated: 2024-07-09

Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)

Not yet recruitingCTIS2024-512318-16-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Patients with colorectal peritoneal metastases with a PCI-score of 1-20

Target: 40Updated: 2026-01-02

Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial

RecruitingCTIS2025-521158-40-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)oesophageal cancer, oesophagogastric junction cancer

Start: 2025-09-12Target: 12Updated: 2025-08-27

Phase 3

Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study

Not yet recruitingCTIS2024-510617-15-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Non-metastatic resectable pancreatic cancer

Target: 378Updated: 2024-09-09

THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDERLINE) RESECTABLE PANCREATIC CANCER (PREOPANC-2 STUDY)

Not yet recruitingCTIS2024-516260-29-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)non-metastatic (borderline) resectable pancreatic cancer

Target: 368Updated: 2024-10-09